We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Oncolab Exhibits Pioneering AMAS Cancer Test at AACC

By LabMedica International staff writers
Posted on 29 Jul 2014
The Oncolab (Boston, MA, USA) laboratory-developed AMAS cancer test is making its AACC debut at this year's 2014 conference. More...
To date, the test, which is a serum-based in vitro immunoassay, has been run for over 60,000 patients and appears to be an emerging tool in the fight against cancer recurrence as well as detection.

There are an estimated 17 million cancer survivors in the US alone, hence there is a race to develop better technologies for identifying whether a cancer has begun to recur, and if so at what rate. There is a clear trend towards the use of immunoassays in cancer diagnostics, as immunotherapy for treatment. The AMAS test fits into these trends by measuring the level of a specific antibody, Anti-Malignin Antibody, which is thought to be produced by the body's immune system in response to nearly all forms of cancer.

Most other cancer immunoassays measure circulating cancer antigens, which become elevated later than the antibody measured in the AMAS test. Therefore, the AMAS Test helps to pick up recurrence at an early stage when levels of anti-malignin antibody are often elevated early in the occurrence and recurrence of cancer. This is a distinctive capability—false positive and false negative rates are under 10%. While the AMAS test does provide guidance to the likely location of the cancer, new high-resolution imaging techniques, more location-specific cancer tests, and clinical signs help the clinician provide patients with a fuller picture of the disease.

Currently, Oncolab provides the test via submission of samples to its CLIA-certified laboratory in Boston. Serum samples must be shipped via overnight courier, using a standardized shipping container and tubes provided at no cost by Oncolab, dry ice obtained at the lab while doing the blood draw, and separation to serum. The test is approved by the US Food and Drug Administration (FDA) and reimbursed by Medicare.

Today, the majority of samples being run are drawn in the US and Canada; overseas labs can also ship samples and are urged to contact Oncolab to get a technical and business relationship started.

The AMAS test, by Oncolab, is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility in Boston. The test is able to detect early cases of cancer recurrence, a major concern for 17 million Americans. This year is the company's debut at the AACC (American Association for Clinical Chemistry), being held in Chicago - booth #4051.

Related Links:

Oncolab



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new test is redefining access to early endometrial cancer detection (Photo courtesy of Shutterstock)

Non-Invasive Liquid-Based Cytology Test Enables Early Endometrial Cancer Detection

Endometrial cancer is the fourth most common cancer among women in the United States, with over 69,000 new cases expected in 2025. Yet many diagnoses occur late, particularly in women who face inconclusive... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.